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S198 Poster Session Ito mobilize or utilizing combination G-CSF and plerixafor for all
pts as upfront mobilization.
Mobilization and Collection
All Patients Plerixafor No PlerixaforPB CD34 day 4
\10 65 47 (72%) 18 (28%)
10-14 11 4 (36%) 7 (64%)
$15 58 3 (5%) 55 (95%)not done* 12 12 0
Day 1 Apheresis yield
(x10[6] CD34/kg)
\1 15 14 (93%) 1 (7%)
\1.5 33 25 (76%) 8 (24%)
$1.5 77 5 (6%) 72 (94%)*12 patients received Plerixafor on the evening of day 4 due to prior
failure to mobilize or high risk of failure111
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Introduction: Addition of rituximab to chemotherapy (CT) for
follicular lymphoma (FL) has been shown to improve many outcome
parameters. Often, high-dose therapy is followed by autologous
stem-cell transplantation (ASCT) after 1, 2 or more relapses. Kang
et al. (BMT (2007) 40, 973) investigated whether prior exposure to
rituximab had any influence on a subsequent ASCT and found no
differences in the outcomes analyzed. However, there has been evi-
dence suggesting that that such prior exposure may alter the pheno-
type of these tumour cells so that they no longer express CD20, and
thus potentially altering their behaviour.
Methods:We performed a retrospective review on all patients hav-
ing received an ASCT at the Ottawa Hospital with an initial diagno-
sis of FL. They were grouped into four categories according to their
prior exposure to or lack of prior exposure to rituximab and accord-
ing to their pre-ASCT diagnosis, non-transformed FL (FL-NT) vs.
transformed (FL-T).
Results: 259 patients who underwent an autoHSCT for FL were di-
vided into 4 groups: 184 FL non-transformed (FL-NT) (31 patients
received rituximab and 153 did not), and 75 FL-transformed (FL-T)
(24 patients received rituximab and 51 did not). The 5-year progres-
sion-free survivals (PFS) were 61.2% and 27.6%, respectively
(p\0.0001) and the overall survivals (OS) were 72.5% and 39.3%,
respectively, (p\0.0001). In the FL-NT group, no differences ex-
isted in PFS or OS between FL-NT rituximab-naı¨ve and rituxi-
mab-treated patients (5-year PFS 61% vs. 64%, p5 0.69; 5-year
OS 73% vs. 68%, p5 0.80).Within the FL-T group, the subsequent
5-year PFS of the rituximab-naive vs. pre-treated groups were 22%
and 55% (p 50.20), respectively, and the 5-year OS were 36% and
51% (p5 0.39), respectively. Prior exposure to R had a positive ef-
fect (Hazard Ratio (HR): 0.44, 95% CI 0.20-0.97, p5 0.04) on
PFS and OS (HR: 0.5, 95% CI 0.21-1.18, p5 0.11).
Conclusion: Pre-treatment with rituximab in FL-NT prior to
ASCTdoes not adversely impact ASCToutcomes.There is a sugges-
tion of an increase in the number of patients with FL-T being trans-
planted in the post-rituximab era and as expected, the FL-T had
a poorer outcome than the FL-NT patients. However, prior expo-
sure to rituximab appeared to demonstrate a trend toward an im-
proved OS within the FL-T group. In summary, previous
rituximab exposuremay be associated with an increased rate of trans-
formation, leading to the poorer outcome of patients originally diag-
nosed with FL-NT.112
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Methods which permit discrimination between viable and apopto-
tic peripheral blood stem cells (PBSC) following cryopreservation
may be important in assessing the quality and engraftment potential
of thawed apheresis product used in autologous transplantation. Pre-
vious studies have shown that cryopreservation results in significant
apoptosis in CD34+ cells and that estimation of PBSC number based
on the expression of the functional stem cell marker, aldehyde dehy-
drogenase (ALDH)may provide a better estimate of engraftment po-
tential in cryopreserved product than CD34 alone. We assessed
whether PBSC subset assessment based upon DilC1, a sensitive
marker of mitochondrial membrane potential and apoptosis, to-
gether with the viability exclusion dye 7-AAD, ALDH activity and
CD34 expression may identify subsets which correlate with short
and long term engraftment parameters following cryopreservation
of PBSC apheresis product and autologous transplantation. 35 pts
(median age 596 9yrs) underwent PBSC collection, high dose che-
motherapy and autologous transplantation for haematological ma-
lignancy. Most pts had multiple myeloma (42%) or NHL (40%).
Post thaw mean infused CD34  106/kg was 4.10 (0.05-10.5) and
ALDH  106/kg 2.28 (0.25-6.5). CD34 viability was 72.3% (11.7-
96.0). Most ALDH+ cells were non-apoptotic as assessed by DilC1
staining, 89.9% (55.6-100.0) vs CD34, 34.5% (3.2-84.7),
(p\0.005), and most ALDH+ cells expressed CD34 (71.3%, 33.9-
97.2). Only the CD34 + ALDH+ subset correlated with time to
ANC. 0.5  109/L, (p5 0.049), though a trend was noted for
CD34 +DilC1+ (p5 0.07). No analysed subset could be significantly
correlated to short term platelet recovery (Pl. 20  10/9L). Long
term (day 100) erythroid (Hb .100 g/L) and platelet engraftment
(Pl. 100  109/L) was strongly correlated to numbers of
CD34 +DilC1+ (p\0.005), CD34 + ALDH+ (p\0.005), and
CD34 + ALDH+DilC1+ (p\0.005) in infused product. Assess-
ments of engraftment potential of cryopreserved PBSC’s based on vi-
able CD34 counts may be uninformative unless markers of apoptotic
activity are included for analysis. In contrast, assessments based on
ALDH activity appear to identify a viable and non-apoptotic stem
cell subset correlated to both short term neutrophil and long term
erythroid and platelet engraftment potential following autologous
transplantation. Markers of apoptosis may be redundant when as-
sessing ALDH activity in autologous PBSC product.113
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Autologous (Auto) and allogeneic (Allo) hematopoietic cell
transplantation (HCT) have been used to cure malignant and
non-malignant conditions for .40 years. Recent advances in
HCT techniques and supportive care, new HCT indications,
and improvements in survival outcomes may have increased access
to and utilization of HCT. We describe the HCT population, uti-
lization and procedure patterns in North American (US and Can-
ada) HCT centers reporting to the CIBMTR from 1994-2005.
We divided the population into six 2-year cohorts (Table). All
data exclude donor lymphocyte infusions. The number of Au-
toHCTs increased by .30% from the mid to late 1990s, then
